Anaveon Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 24

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 9

Anaveon General Information

Description

Operator of a biopharmaceutical company intended to offer treatments for diseases with immune system dysfunction and transform cytokines into treatments. The company focuses on cytokine-based therapies that enhance patients' immune systems and also offers therapies for conditions driven by inflammation and autoimmunity, enabling cancer patients to have therapeutic benefits against a wide variety of diseases.

Contact Information

Website
www.anaveon.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Technologiepark Basel
  • Hochbergerstrasse 60C
  • 4057 Basel
  • Switzerland
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Technologiepark Basel
  • Hochbergerstrasse 60C
  • 4057 Basel
  • Switzerland

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Anaveon Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Secondary Transaction - Private 01-Apr-2026 Completed Pre-Clinical Trials
4. Early Stage VC (Series B) 17-Dec-2021 Completed Pre-Clinical Trials
3. Early Stage VC (Series A) 26-Feb-2019 Completed Pre-Clinical Trials
2. Accelerator/Incubator 31-Jan-2018 $156K $156K Completed Pre-Clinical Trials
1. University Spin-Out 01-Jan-2017 Completed Startup
To view Anaveon’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Anaveon Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biopharmaceutical company intended to offer treatments for diseases with immune system dysfunction and tra
Drug Discovery
Basel, Switzerland
24 As of 2026

Richmond, CA
 

Wilmington, DE
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Anaveon Competitors (86)

One of Anaveon’s 86 competitors is Sangamo Therapeutics, a Formerly VC-backed company based in Richmond, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Sangamo Therapeutics Formerly VC-backed Richmond, CA
Ayala Pharmaceuticals Corporation Wilmington, DE
Oxford Biotherapeutics Private Equity-Backed Oxford, United Kingdom
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
T3 Pharmaceuticals Formerly VC-backed Allschwil, Switzerland
You’re viewing 5 of 86 competitors. Get the full list »

Anaveon Patents

Anaveon Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4671273-A1 Proximity activated interleukin 21 Pending 26-Jun-2024
WO-2026003219-A1 Proximity activated interleukin 21 Pending 26-Jun-2024
EP-4491631-A1 Anti-pd-1 antibody binding domain and immunoconjugate Inactive 13-Jul-2023
EP-4431525-A1 Il-2 fusion protein Inactive 16-Mar-2023
EP-4638498-A1 Anti-pd-1 antibody antigen-binding domain and immunoconjugate Pending 22-Dec-2022 C07K16/246
To view Anaveon’s complete patent history, request access »

Anaveon Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Anaveon Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
Blue Owl Capital Asset Manager Minority
Cowen Healthcare Investments Venture Capital Minority
Forbion Venture Capital Minority
Pfizer Ventures Corporate Venture Capital Minority
Pontifax Venture Capital Venture Capital Minority
You’re viewing 5 of 9 investors. Get the full list »

Anaveon FAQs

  • When was Anaveon founded?

    Anaveon was founded in 2017.

  • Where is Anaveon headquartered?

    Anaveon is headquartered in Basel, Switzerland.

  • What is the size of Anaveon?

    Anaveon has 24 total employees.

  • What industry is Anaveon in?

    Anaveon’s primary industry is Drug Discovery.

  • Is Anaveon a private or public company?

    Anaveon is a Private company.

  • What is Anaveon’s current revenue?

    The current revenue for Anaveon is .

  • How much funding has Anaveon raised over time?

    Anaveon has raised $155M.

  • Who are Anaveon’s investors?

    Blue Owl Capital, Cowen Healthcare Investments, Forbion, Pfizer Ventures, and Pontifax Venture Capital are 5 of 9 investors who have invested in Anaveon.

  • Who are Anaveon’s competitors?

    Sangamo Therapeutics, Ayala Pharmaceuticals, Oxford Biotherapeutics, Inovio Pharmaceuticals, and T3 Pharmaceuticals are some of the 86 competitors of Anaveon.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process